BioWorld

Mdm2-Katushka-S2 reporter mouse model for studying MDM2-p53 negative feedback loop in cancer

Researchers from Walter and Eliza Hall Institute of Medical Research, The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study ...
ascopubs.org

Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non–Small-Cell Lung Cancer

Our data suggest that immunopositivity of p14ARF together with a low expression of MDM2 contributes to accumulation of the wild-type p53, and that deregulation of the p53-MDM2-p14ARF pathway is ...
ascopubs.org

Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs ...

Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis. This is an ASCO Meeting Abstract from the 2024 ...
Nasdaq

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown to ...
News Medical

Computational exploration of natural product–based MDM2 inhibitors for p53 reactivation

This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...